P2X7 Blockade Attenuates Murine Lupus Nephritis by Inhibiting Activation of the NLRP3/ASC/Caspase 1 Pathway
Open Access
- 10 September 2013
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (12), 3176-3185
- https://doi.org/10.1002/art.38174
Abstract
Objective The NLRP3 inflammasome plays key roles in inflammation and autoimmunity, and purinergic receptor P2X7 has been proposed to be upstream of NLRP3 activation. The aim of the present study, using murine models, was to investigate whether the P2X7/NLRP3 inflammasome pathway contributes to the pathogenesis of lupus nephritis (LN). Methods MRL/lpr mice were treated with the selective P2X7 antagonist brilliant blue G (BBG) for 8 weeks. Following treatment, the severity of renal lesions, production of anti–double‐stranded DNA (anti‐dsDNA) antibodies, rate of survival, activation of the NLRP3/ASC/caspase 1 inflammasome pathway, and ratio of Th17 cells to Treg cells were evaluated. P2X7‐targeted small interfering RNA (siRNA) was also used for in vivo intervention. Similar evaluations were carried out in NZM2328 mice, a model of LN in which the disease was accelerated by administration of adenovirus‐expressing interferon‐α (AdIFNα). Results Significant up‐regulation of P2X7/NLRP3 inflammasome signaling molecules was detected in the kidneys of MLR/lpr mice as compared with normal control mice. Blockade of P2X7 activation by BBG suppressed NLRP3/ASC/caspase 1 assembly and the subsequent release of interleukin‐1β (IL‐1β), resulting in a significant reduction in the severity of nephritis and circulating anti‐dsDNA antibodies. The lifespan of the treated mice was significantly prolonged. BBG treatment reduced the serum levels of IL‐1β and IL‐17 and the Th17:Treg cell ratio. Similar results were obtained by specific siRNA silencing of P2X7 in vivo. The effectiveness of BBG treatment in modulating LN was confirmed in NZM2328 mice with AdIFNα‐accelerated disease. Conclusion Activation of the P2X7 signaling pathway accelerates murine LN by activating the NLRP3/ASC/caspase 1 inflammasome, resulting in increased IL‐1β production and enhanced Th17 cell polarization. Thus, targeting of the P2X7/NLRP3 pathway should be considered as a novel therapeutic strategy in patients with lupus.Keywords
This publication has 44 references indexed in Scilit:
- The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouseProceedings of the National Academy of Sciences of the United States of America, 2011
- Inhibition of Neuronal Voltage-Gated Sodium Channels by Brilliant Blue GMolecular Pharmacology, 2011
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- The NZM2410-derived lupus susceptibility locus Sle2c1 increases Th17 polarization and induces nephritis in fas-deficient miceArthritis & Rheumatism, 2010
- Interleukin-1β Produced in Response to Islet Autoantigen Presentation Differentiates T-Helper 17 Cells at the Expense of Regulatory T-CellsDiabetes, 2010
- Interferon‐α accelerates murine systemic lupus erythematosus in a T cell–dependent mannerArthritis & Rheumatism, 2010
- Proinflammatory T helper type 17 cells are effective B-cell helpersProceedings of the National Academy of Sciences of the United States of America, 2010
- Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6–lpr/lpr MiceThe Journal of Immunology, 2010
- Inflammasome-independent Role of Apoptosis-associated Speck-like Protein Containing a CARD (ASC) in T Cell Priming Is Critical for Collagen-induced ArthritisPublished by Elsevier BV ,2010
- Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritisClinical and Experimental Immunology, 2009